{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:57:15Z","timestamp":1776326235923,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Meibomian gland dysfunction is the most common etiology of dry eye disease worldwide and intense pulsed light appears to be a promising treatment with encouraging results. Lacrystim\u00ae is a new IPL device (CE marking in 2019) and no studies have yet been published on it. We propose the first study on this device with an objective assessment of its efficacy and an extended follow-up over 6\u2009months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients presenting with a dry eye disease (DED) with stable mild to moderate MGD and having received Lacrystim\u00ae treatment between june 2019 and june 2020 were included. 3 IPL sessions were performed at D0, D15 and D45 with 4 shots per side at a fluence of 8\u2009mJ\/cm2. DED clinical evaluation was performed at D0, D15, D45, 3rd month and 6th month: Oxford scale and break up time, Schirmer test and Ocular Surface Disease Index (OSDI) questionnaire. Lacrydiag\u00ae imaging device carried out an objective examination of tear film: interferometry, meibography, tear meniscus height and non-invasive break up time (NIBUT). The primary endpoint was the evolution in NIBUT between the first visit D0 and 3rd month. Data collection was done retrospectively. Statistical analysis was done using a linear mixed-effects model and a non-parametric linear mixed-effects model (R software).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forthy five consecutive patients were included. NIBUT significantly increased between D0 and 3rd month: mean difference of 1.63\u2009seconds, IC95% [0.51; 2.62], (<jats:italic>p\u2009=<\/jats:italic>\u00a00.002) with a prolonged effect at 6th month. OSDI and OXFORD scores and interferometry were also significantly improved at 3rd month and 6th month. There was no significant change in BUT, Schirmer test and tear meniscus height. No adverse event was noted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IPL delivered by Lacrystim\u00ae appears effective and safe to treat MGD although a randomized controlled trial is needed to validate its results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This work was approved by a local ethics committee \u201cTerre d\u2019\u00e9thique\u201d (institutional review board number: IRBN672019\/CHUSTE) and registered on the <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrial.gov\">clinicaltrial.gov<\/jats:ext-link> website (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04147962?cond=intense+pulsed+light&amp;cntry=FR&amp;draw=2&amp;rank=1\">NCT04147962<\/jats:ext-link>, 01\/11\/2019).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02531-7","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T07:14:24Z","timestamp":1659770064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A retrospective study of the efficacy of intense pulsed light delivered by the Lacrystim\u00ae for meibomian gland dysfunction therapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Marie-Caroline","family":"Trone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Garcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Ollier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Thuret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"issue":"4","key":"2531_CR1","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1167\/iovs.10-6997h","volume":"52","author":"PA Asbell","year":"2011","unstructured":"Asbell PA, Stapleton FJ, Wickstr\u00f6m K, Akpek EK, Aragona P, Dana R, et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Invest Ophthalmol Vis Sci. mars. 2011;52(4):2065\u201385.","journal-title":"Invest Ophthalmol Vis Sci. mars"},{"issue":"3","key":"2531_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438\u2013510.","journal-title":"Ocul Surf"},{"key":"2531_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ajo.2019.02.024","volume":"207","author":"R Arita","year":"2019","unstructured":"Arita R, Mizoguchi T, Kawashima M, Fukuoka S, Koh S, Shirakawa R, et al. Meibomian gland dysfunction and dry eye are similar but different based on a population-based study: the Hirado-Takushima study in Japan. Am J Ophthalmol. 2019;207:410\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2531_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.survophthal.2019.08.007","volume":"65","author":"S Sabeti","year":"2020","unstructured":"Sabeti S, Kheirkhah A, Yin J, Dana R. Management of meibomian gland dysfunction: a review. Surv Ophthalmol avr. 2020;65(2):205\u201317.","journal-title":"Surv Ophthalmol avr"},{"key":"2531_CR5","first-page":"29","volume":"9","author":"Z Husain","year":"2016","unstructured":"Husain Z, Alster TS. The role of lasers and intense pulsed light technology in dermatology. Clin Cosmet Investig Dermatol. 2016;9:29\u201340.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2531_CR6","doi-asserted-by":"crossref","unstructured":"Paasch U, Schwandt A, Seeber N, Kautz G, Grunewald S, Haedersdal M. New lasers and light sources - old and new risks? J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG mai 2017;15(5):487\u2013496.","DOI":"10.1111\/ddg.13238"},{"issue":"3","key":"2531_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575\u2013628.","journal-title":"Ocul Surf."},{"key":"2531_CR8","doi-asserted-by":"crossref","unstructured":"Liu R, Rong B, Tu P, Tang Y, Song W, Toyos R, et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating Meibomian gland dysfunction. Am J Ophthalmol nov 2017;183:81\u201390.","DOI":"10.1016\/j.ajo.2017.08.021"},{"issue":"10","key":"2531_CR9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.7150\/ijms.44288","volume":"17","author":"A Suwal","year":"2020","unstructured":"Suwal A, Hao JL, Zhou DD, Liu XF, Suwal R, Lu CW. Use of intense pulsed light to mitigate Meibomian gland dysfunction for dry eye disease. Int J Med Sci. 2020;17(10):1385\u201392.","journal-title":"Int J Med Sci"},{"key":"2531_CR10","doi-asserted-by":"crossref","unstructured":"Tashbayev B, Yazdani M, Arita R, Fineide F, Utheim TP. Intense pulsed light treatment in meibomian gland dysfunction: A concise review. Ocul Surf. 3 juill 2020;","DOI":"10.1016\/j.jtos.2020.06.002"},{"key":"2531_CR11","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2147\/OPTH.S139894","volume":"11","author":"SJ Dell","year":"2017","unstructured":"Dell SJ. Intense pulsed light for evaporative dry eye disease. Clin Ophthalmol Auckl NZ. 2017;11:1167\u201373.","journal-title":"Clin Ophthalmol Auckl NZ"},{"issue":"1","key":"2531_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/ICL.0000000000000680","volume":"46","author":"PY Lam","year":"2020","unstructured":"Lam PY, Shih KC, Fong PY, Chan TCY, Ng ALK, Jhanji V, et al. A review on evidence-based treatments for Meibomian gland dysfunction. Eye Contact Lens janv. 2020;46(1):3\u201316.","journal-title":"Eye Contact Lens janv"},{"key":"2531_CR13","doi-asserted-by":"crossref","unstructured":"Fishman HA, Periman LM, Shah AA. Real-Time Video Microscopy of In Vitro Demodex Death by Intense Pulsed Light. Photobiomodulation Photomed Laser Surg. 27 janv 2020;","DOI":"10.1089\/photob.2019.4737"},{"issue":"3","key":"2531_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","volume":"15","author":"JS Wolffsohn","year":"2017","unstructured":"Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3):539\u201374.","journal-title":"Ocul Surf."},{"issue":"4","key":"2531_CR15","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","volume":"52","author":"A Tomlinson","year":"2011","unstructured":"Tomlinson A, Bron AJ, Korb DR, Amano S, Paugh JR, Pearce EI, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci mars. 2011;52(4):2006\u201349.","journal-title":"Invest Ophthalmol Vis Sci mars"},{"issue":"4","key":"2531_CR16","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1109\/JBHI.2013.2294732","volume":"18","author":"B Remeseiro","year":"2014","unstructured":"Remeseiro B, Bolon-Canedo V, Peteiro-Barral D, Alonso-Betanzos A, Guijarro-Berdi\u00f1as B, Mosquera A, et al. A methodology for improving tear film lipid layer classification. IEEE J Biomed Health Inform juill. 2014;18(4):1485\u201393.","journal-title":"IEEE J Biomed Health Inform juill"},{"key":"2531_CR17","doi-asserted-by":"crossref","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol Chic Ill 1960. mai 2000;118(5):615\u2013621.","DOI":"10.1001\/archopht.118.5.615"},{"issue":"2","key":"2531_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jtos.2012.01.007","volume":"10","author":"I Guillemin","year":"2012","unstructured":"Guillemin I, Begley C, Chalmers R, Baudouin C, Arnould B. Appraisal of patient-reported outcome instruments available for randomized clinical trials in dry eye: revisiting the standards. Ocul Surf avr. 2012;10(2):84\u201399.","journal-title":"Ocul Surf avr"},{"key":"2531_CR19","doi-asserted-by":"crossref","unstructured":"Noguchi K, GEL YR, Brunner E, et al. An R software package for the nonparametric analysis of longitudinal data in factorial experiments. J Stat Softw. 2012;50(12).","DOI":"10.18637\/jss.v050.i12"},{"key":"2531_CR20","unstructured":"Dessau RB, Pipper CB. [\u201cR\"--project for statistical computing]. Ugeskr Laeger. 28 janv 2008;170(5):328\u201330."},{"key":"2531_CR21","doi-asserted-by":"crossref","unstructured":"Wickham H. ggplot2. WIREs Comput Stat 4 f\u00e9vr 2011;3(2):180\u2013185.","DOI":"10.1002\/wics.147"},{"issue":"6","key":"2531_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archderm.1988.01670060015008","volume":"124","author":"TB Fitzpatrick","year":"1988","unstructured":"Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol juin. 1988;124(6):869\u201371.","journal-title":"Arch Dermatol juin"},{"key":"2531_CR23","first-page":"1910694","volume":"2016","author":"X Jiang","year":"2016","unstructured":"Jiang X, Lv H, Song H, Zhang M, Liu Y, Hu X, et al. Evaluation of the safety and effectiveness of intense pulsed light in the treatment of Meibomian gland dysfunction. J Ophthalmol. 2016;2016:1910694.","journal-title":"J Ophthalmol"},{"issue":"2","key":"2531_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1120672118817687","volume":"30","author":"EE Karaca","year":"2020","unstructured":"Karaca EE, Evren Kemer \u00d6, \u00d6zek D. Intense regulated pulse light for the meibomian gland dysfunction. Eur J Ophthalmol mars. 2020;30(2):289\u201392.","journal-title":"Eur J Ophthalmol mars"},{"issue":"12","key":"2531_CR25","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1097\/ICO.0000000000001687","volume":"37","author":"R Arita","year":"2018","unstructured":"Arita R, Mizoguchi T, Fukuoka S, Morishige N. Multicenter study of intense pulsed light therapy for patients with refractory Meibomian gland dysfunction. Cornea d\u00e9c. 2018;37(12):1566\u201371.","journal-title":"Cornea d\u00e9c"},{"key":"2531_CR26","doi-asserted-by":"crossref","unstructured":"Guilloto Caballero S, Garc\u00eda Madrona JL, Colmenero RE. Effect of pulsed laser light in patients with dry eye syndrome. Arch Soc Espanola Oftalmol. 92(11):509\u201315.","DOI":"10.1016\/j.oftale.2017.03.012"},{"issue":"1","key":"2531_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/pho.2014.3819","volume":"33","author":"R Toyos","year":"2015","unstructured":"Toyos R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg janv. 2015;33(1):41\u20136.","journal-title":"Photomed Laser Surg janv"},{"key":"2531_CR28","doi-asserted-by":"crossref","unstructured":"Craig JP, Chen YH, Turnbull PRK. Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 12 f\u00e9vr 2015;56(3):1965\u20131970.","DOI":"10.1167\/iovs.14-15764"},{"key":"2531_CR29","first-page":"3684963","volume":"2020","author":"S Wei","year":"2020","unstructured":"Wei S, Ren X, Wang Y, Chou Y, Li X. Therapeutic effect of intense pulsed light (IPL) combined with Meibomian gland expression (MGX) on Meibomian gland dysfunction (MGD). J Ophthalmol. 2020;2020:3684963.","journal-title":"J Ophthalmol"},{"issue":"3","key":"2531_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/ICO.0000000000000735","volume":"35","author":"S Vegunta","year":"2016","unstructured":"Vegunta S, Patel D, Shen JF. Combination therapy of intense pulsed light therapy and Meibomian gland expression (IPL\/MGX) can improve dry eye symptoms and Meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea mars. 2016;35(3):318\u201322.","journal-title":"Cornea mars"},{"issue":"1","key":"2531_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jtos.2018.11.004","volume":"17","author":"R Arita","year":"2019","unstructured":"Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf. 2019;17(1):104\u201310.","journal-title":"Ocul Surf."},{"issue":"3","key":"2531_CR32","first-page":"325","volume":"39","author":"Y Piyacomn","year":"2020","unstructured":"Piyacomn Y, Kasetsuwan N, Reinprayoon U, Satitpitakul V, Tesapirat L. Efficacy and safety of intense pulsed light in patients with Meibomian gland dysfunction-a randomized, double-masked. Sham-Controlled Clinical Trial Cornea. 2020;39(3):325\u201332.","journal-title":"Sham-Controlled Clinical Trial Cornea"},{"issue":"4","key":"2531_CR33","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.jcjo.2012.01.019","volume":"47","author":"H Jewsbury","year":"2012","unstructured":"Jewsbury H, Morgan F. Uveitis and iris photoablation secondary to intense pulsed light therapy. Can J Ophthalmol J Can Ophtalmol ao\u00fbt. 2012;47(4):e13\u20134.","journal-title":"Can J Ophthalmol J Can Ophtalmol ao\u00fbt"},{"issue":"4","key":"2531_CR34","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1097\/IOP.0000000000001142","volume":"34","author":"CY Chang","year":"2018","unstructured":"Chang CY, Sheu SJ. Choroidal neovascularization secondary to intense pulsed light injury. Ophthal Plast Reconstr Surg. ao\u00fbt. 2018;34(4):e129\u201331.","journal-title":"Ophthal Plast Reconstr Surg. ao\u00fbt"},{"issue":"4","key":"2531_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/IOP.0b013e31820c6e23","volume":"27","author":"WW Lee","year":"2011","unstructured":"Lee WW, Murdock J, Albini TA, O\u2019brien TP, Levine ML. Ocular damage secondary to intense pulse light therapy to the face. Ophthal Plast Reconstr Surg ao\u00fbt. 2011;27(4):263\u20135.","journal-title":"Ophthal Plast Reconstr Surg ao\u00fbt"},{"key":"2531_CR36","doi-asserted-by":"crossref","unstructured":"Yan X, Hong J, Jin X, Chen W, Rong B, Feng Y, et al. The Efficacy of Intense Pulsed Light Combined With Meibomian Gland Expression for the Treatment of Dry Eye Disease Due to Meibomian Gland Dysfunction: A Multicenter, Randomized Controlled Trial. Eye Contact Lens. 19 mai 2020;","DOI":"10.1097\/ICL.0000000000000711"},{"issue":"2","key":"2531_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/photob.2018.4509","volume":"37","author":"D Li","year":"2019","unstructured":"Li D, Lin SB, Cheng B. Intense pulsed light treatment for Meibomian gland dysfunction in skin types III\/IV. Photobiomodulation Photomed Laser Surg f\u00e9vr. 2019;37(2):70\u20136.","journal-title":"Photobiomodulation Photomed Laser Surg f\u00e9vr"},{"key":"2531_CR38","unstructured":"Rennick S, Adcock L. Intense Pulsed Light Therapy for Meibomian Gland Dysfunction: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 [cit\u00e9 12 d\u00e9c 2019]. (CADTH rapid response reports). Disponible sur: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531789\/"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02531-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02531-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02531-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T07:14:32Z","timestamp":1659770072000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02531-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2531"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02531-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was approved by a local ethics committee called \u201cTerre d\u2019\u00e9thique\u201d (institutional review board number: IRBN672019\/CHUSTE) and registered on the  website (NCT04147962, 01\/11\/2019). We confirm that all methods have been applied in accordance with the relevant guidelines and regulations. Informed consent for participation was obtained from all the participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This paper contains images of patients, we confirm that a statement of informed consent to publish these images were gathered from patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Marie-Caroline TRONE, Gilles THURET and Philippe GAIN received fees from Quantel Medical to design the retrospective analysis chart. Quantel Medical played no role in data analysis, interpretation or writing of this work. Other authors have no competing interest.All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"335"}}